Keynesonomics
Long

DVAX -Bullish RSI Divergence May Signal an Impending Move Higher

NASDAQ:DVAX   DYNAVAX TECHNOLOGIES CORP
31 0 0
Eddie Gray ( CEO             ) & the rest of Dynavax's "A-Team" are unequivocally committed and, IMO, well in the process of expanding/creating a diversified PL within a first class biotech franchise. I'm a firm believer that management's rigorous approach to drug development in the field of TLR biology and immune system modulation to attack the challenges of infectious and inflammatory diseases and cancer will extract maximum shareholder value over time; hence, also believe that shares are grossly undervalued at current levels. My LT             PT is actually $62.79 (not shown on this chart) but have provided several reference points (R-1 - R-5) that I think, eventually, will be achieved. Disclosure: Long via common equity . For reference only & not investment advice.
Ideas Scripts Chart
United States
United Kingdom
India
España
Italia
Brasil
Россия
Türkiye
日本
한국
Home Stock Screener Economic Calendar How It Works Chart Features House Rules Moderators For the WEB Widgets Stock Charting Library Priority Support Feature Request Blog & News FAQ Help & Wiki Twitter
Private Messages Chat Ideas Published Followers Following Priority Support Public Profile Profile Settings Billing Sign Out